Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Business & Finance › Goldman's Snider Expects Double-Digit S&P Earnings Growth
Business & Finance

Goldman's Snider Expects Double-Digit S&P Earnings Growth

Bloomberg Markets Tuesday 22 September 2026, 14:44 UTC 1 min read
Key Points

Goldman Sachs Chief US Equity Strategist Ben Snider says investors should not be anxious. He expects S&P 500 companies to report double-digit earnings growth starting next week. He also talks about the AI trade on "Bloomberg Open Interest."

Goldman Sachs Chief US Equity Strategist Ben Snider says investors should not be anxious. He expects S&P 500 companies to report double-digit earnings growth starting next week. He also talks about the AI trade on "Bloomberg Open Interest." (Source: Bloomberg)
Goldman's Snider Expects (ORG) Goldman Sachs (ORG) US (LOCATION) Ben Snider (PERSON)
Originally published by Bloomberg Markets Read original →

Related Stories

Short-End Treasuries Become Popular Bet on Fed Inflation Win

Investors in the US Treasury market are shifting their focus to owning shorter-dated government bonds, a bet that the Federal Reserve will eventually emerge victorious in its fight against inflation. Gennadiy Goldberg, Head of US Rates Strategy at TD Securities, discusses how the current rate hiking cycle might evolve and where the 10-year could finish the year.

Bloomberg Markets 29m ago

If you start writing today, there's no way to know if you can write without AI

Writing with AI: What's the Best Approach? To me, AI writing always results in this: They always look nice at first sight, but over time, they look all the same: complex, unnatural, and busy. Same as DALL-E images.

Hacker News 38m ago

Fed's Williams Says Shift to Central Clearing Ahead of Schedule

Federal Reserve Bank of New York President John Williams says the shift to central clearing for US Treasuries and Treasury-collateralized repurchase agreements is ahead of schedule.

Bloomberg Markets 39m ago

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard their futuresSome of Europe’s biggest pharmaceutical companies have said the continent is “losing ground” to rivals including the US and China in developing new drugs and attracting investment. The chairs of nine companies, including Britain’s AstraZeneca, GSK and Denmark’s Novo Nordisk, wrote to Andy Burnham and the national leaders of other European countries on Tuesday to call for action to...

The Guardian Business 43m ago